Posts Tagged ‘esclerosis múltiple’

Categories

Posted in:

Wednesday January 04th, 2017

A new drug has been developed for the treatment of autoimmune diseases

IDIBAPS researchers have participated in a study that shows how a new experimental drug could curb a wide variety of autoimmune diseases such as asthma, psoriasis, Crohn’s disease or multiple sclerosis without blocking the body’s natural response against infections caused by pathogens.

Read the rest of this entry »

Comments Closed
Friday September 16th, 2016

IDIBAPS shares one milion euros to develop a project on Multiple Sclerosis

Neuroscientist Elena H. Martínez-Lapiscina, researcher of the IDIBAPS, shares with other XXXX experts a million euros that the Grant for Multiple Sclerosis Innovation (GMSI) award to the best translational research projects which contribute to increase or improve the knowledge on Multiple Sclerosis ( MS) and the development of new therapies. Dr. Elena H. Martínez-Lapiscina project, presented at the ECTRIMS congress (European Comitee for Treatment and Research in Multiple Sclerosis ), aims to give a boost to the understanding of the disease and the developement of therapies through the analysis of the retina of affected patients.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday May 24th, 2016

Diagnosis through the retina can predict the evolution of patients with Multiple Sclerosis

A study led by IDIBAPS researchers has shown the usefulness of optical coherence tomography (OCT), a diagnostic imaging technique widely used in ophthalmology, for monitoring patients with multiple sclerosis (MS). The analysis of the retina with this technique can determine the risk of clinical worsening of those patients. Dr. Pablo Villoslada, head of the IDIBAPS Pathogenesis and new treatments in Multiple Sclerosis, and Dr. Elena H. Martinez-Lapiscina, researcher of the same group and head of the Visual Pathway Lab, coordinate this article published in The Lancet Neurology. Researchers from centers in Spain, Italy, France, Germany, Czech Republic, Holland, Canada and the United States have been involved in this study.

Read the rest of this entry »

Comments Closed
Monday July 27th, 2015

Begins a clinical trial of a new technique to treat Multiple Sclerosis and Neuromyelitis Optica

The Spanish Agency for Medicines and Health Products (AEMPS) has approved a clinical trial in humans with an Antigen-Specific therapy with dendritic cells, a pioneering technique for the treatment of Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) in a more effective way and with fewer side effects. Dr. Pablo Villoslada, head of the IDIBAPS group Pathogenesis and new treatments in multiple sclerosis, and Dr. Daniel Benitez, researcher at the Inflammatory bowel disease IDIBAPS team, coordinate this trial led by the Hospital Clinic and driven by the Multiple Sclerosis Affected Group Foundation (GAEM) and “la Caixa” Foundation.

Read the rest of this entry »

Comments Closed
Friday July 03rd, 2015

Researchers from IDIBAPS and Hospital Clínic create the first application containing all the available knowledge on Multiple Sclerosis

Researchers from IDIBAPS and Hospital Clinic of Barcelona have created the first ontology that contains knowledge about Multiple Sclerosis (MS) to advance in translational and clinical research about this disease. This tool allows gathering useful information about the treatments or diseases associated with MS which can be found both in scientific articles and medical records. In the study, coordinated by Dr. Pablo Villoslada, head of the IDIBAPS group Pathogenesis and new treatments in multiple sclerosis, Dr. Xavier Pastor and Dr. Raimundo Lozano form the Medical Informatics Unit of Hospital Clinic, and Dr. Albert Saiz, from the Neurology Department at the hospital, have participated.

Read the rest of this entry »

Comments Closed
Wednesday December 04th, 2013

The study of the retina offers a noninvasive way to visualize the evolution of multiple sclerosis

Neurodegenerative diseases are chronic and still lacking an effective treatment, so they have become a growing concern in our aging society. The lack of therapies adds to the difficulty of studying the effect of new drugs on the brain, because it is not possible to perform a complete diagnosis and pathological study before the death of the patient. The Annals of Neurology published a paper showing that it is possible to monitor the evolution of MS through the retina. Dr. íñigo Gabilondo is the first author of the work, while the last one is Dr. Pablo Villoslada, head of Multiple Sclerosis, Pathogenesis and New Therapies Group at the IDIBAPS’ Neuroimmunology Program. The work was done in collaboration with the Department of Neurology and Ophthalmology at Hospital Clinic of Barcelona, which form the Visual Pathway Laboratory, funded by the Instituto de Salud Carlos III.

Read the rest of this entry »

Comments Closed
Page 1 of 212